SC
ASMB icon

Sophrosyne Capital’s Assembly Biosciences ASMB Stock Holding History

Sophrosyne Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,681
Closed -$637K – 66
2013
Q3 		$637K Sell
3,681
-6,038
-62% -$925K 0.42% 46
2013
Q2 		$1.4M Buy
+9,719
New +$1.52M 1.1% 26

Other funds holding ASMB

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sophrosyne Capital's ASMB Position: Q4 2013 in Review

Sophrosyne Capital sold out of Assembly Biosciences (ASMB) in Q4 2013, closing a stake of 3,681 shares — an estimated $637K sold.

Sophrosyne Capital first reported a position in ASMB in Q2 2013 and held it in 2 quarters. The position peaked at $1.4M in Q2 2013. 34 funds tracked by Wall St. Rank hold ASMB as of Q4 2013.

  • Sophrosyne Capital reported no remaining Assembly Biosciences position as of Q4 2013 after selling out during the quarter.
  • Sophrosyne Capital sold 3,681 Assembly Biosciences shares in Q4 2013, an estimated $637K.
  • Sophrosyne Capital first reported a position in Assembly Biosciences in Q2 2013 and held it in 2 quarters.
  • Sophrosyne Capital's Assembly Biosciences position peaked at $1.4M in Q2 2013.
  • 34 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2013.

Based on Sophrosyne Capital's 13F filing for Q4 2013, filed 13 Feb 2014.